(HealthDay News) -- Women who develop breast tenderness after starting combination estrogen and progestin menopause therapy have a 33 percent higher risk of developing breast cancer than those who don't experience breast tenderness, a new study says.
It also found that new-onset breast tenderness was not associated with increased breast cancer risk among women taking estrogen alone.
The findings, based on an analysis of data from more than 16,600 women on the combination therapy and nearly 10,750 taking estrogen alone, appear in the Nov. 17 online edition of the journal Breast Cancer Research and Treatment.
"This study showed that developing new breast tenderness after the start of hormone therapy was associated with increased breast cancer risk only in women on the combination estrogen plus progestin therapy, not estrogen therapy alone," study first author Dr. Carolyn Crandall, a professor of general internal medicine and a scientist with the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, said in a UCLA news release.
However, the association between breast tenderness and increased cancer risk does not mean that there is a cause-and-effect relationship. Read more...
AyurGold for Healthy Blood
No comments:
Post a Comment